Lyon, France-based biotech company Brenus Pharma has announced the study design of “BreAK-CRC,” a first-in-human trial of its lead candidate, STC-1010, for colorectal cancer. The trial will evaluate the safety and efficacy of STC-1010, an immunotherapeutic approach based on a cancer vaccine mechanism.

STC-1010 has shown promising preclinical results, and the Phase I/IIA BreAK-CRC trial will enroll patients with unresectable advanced or metastatic colorectal cancer, the second leading cause of cancer mortality worldwide. The trial will assess the tolerability and efficacy of STC-1010, combined with immunostimulants and chemotherapy.

Dr. François Ghiringhelli of Centre Georges-François Leclerc, University of Burgundy, discussed the importance of BreAK-CRC, as current immunotherapies are only effective in a small subset of colorectal cancer patients.

The study design was presented at the recent ASCO annual meeting in Chicago. The trial protocol has been reviewed by the French National Health Authority, and submission of the Clinical Trial Application through the European Union clinical trial information system is underway.

Brenus Pharma’s pioneering Stimulated-Tumor-Cell (STC) platform aims to develop a new generation of immunotherapies against cancer. The STC platform imitates the conditions of cancer relapse in vitro, allowing the patient’s immune system to learn about tumor evolution and resistance mechanisms.

Source link: http://www.businesswire.com/news/home/20240613547215/en/ASCO-2024-Brenus-Pharma-Presented-%E2%80%9CBreAK-CRC%E2%80%9D-First-in-human-FIH-Phase-IIIA-Trial-of-STC-1010-a-Next-generation-Cancer-Vaccine-Targeting-mCRC

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.